多发性骨髓瘤患者外周血NLR水平与T淋巴细胞亚群的相关性及对预后的影响

苏传勇; 陶叠宏; 任莉; 郭淑萍; 周雯霏; 吴海英; 蒋慧芳

doi:10.16766/j.cnki.issn.1674-4152.002314

多发性骨髓瘤患者外周血NLR水平与T淋巴细胞亚群的相关性及对预后的影响

doi: 10.16766/j.cnki.issn.1674-4152.002314

浙江省立同德医院血液科，浙江杭州 310012

基金项目:

浙江省医药卫生科技计划项目 2019KY049

浙江省“十三五”中医药重点专科资助项目 2A11952

详细信息

通讯作者:
蒋慧芳, E-mail: jhf501@139.com

中图分类号: R733.3 R730.7
计量
- 文章访问数: 445
- HTML全文浏览量: 271
- PDF下载量: 36
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-17
- 网络出版日期: 2022-03-04

Correlation between peripheral blood neutrophil to lymphocyte ratio level and T lymphocyte subsets in patients with multiple myeloma and its impact on prognosis

Department of Hematology, Zhejiang Tongde Hospital, Hangzhou, Zhejiang 310012, China

摘要

摘要: 目的探讨多发性骨髓瘤(multiple myeloma，MM)患者外周血中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio，NLR)水平与T淋巴细胞亚群的相关性及对预后的影响。方法选择2016年6月—2018年1月在浙江省立同德医院接受诊治的80例MM患者，设为MM组；选择同期在浙江省立同德医院体检的健康者60例，设为健康对照组。比较2组研究对象NLR水平、外周血T细胞亚群及NK细胞水平，Pearson法分析MM组NLR与T细胞亚群水平的相关性。另将MM组分为高NLR水平组(NLR≥2.69，38例)和低NLR水平组(NLR < 2.69，42例)，进行2组生存曲线绘制及生存率比较。结果 MM组NLR、CD8⁺水平明显高于健康对照组[2.69±0.74 vs. 1.72±0.45, (44.34±5.04)% vs. (25.36±3.54)%, t=9.614、26.133，均P < 0.05]，CD3⁺、CD4⁺、CD4⁺/CD8⁺水平明显低于健康对照组(均P < 0.05)，NK细胞水平比较差异无统计学意义(P>0.05)。MM患者NLR水平与CD3⁺、CD4⁺、CD4⁺/CD8⁺呈负相关(r=-0.483、-0.481、-0.595，均P < 0.05)，与CD8⁺呈正相关(r=0.318，P < 0.05)。高NLR组2年生存率、2年无进展生存率明显低于低NLR组(均P < 0.05)。结论 MM患者CD3⁺、CD4⁺、CD4⁺/CD8⁺水平明显低于健康人群，NLR、CD8⁺水平明显高于健康人群，机体NLR水平与患者免疫功能密切相关，高NLR水平提示MM患者预后不良。
- 多发性骨髓瘤 /
- 中性粒细胞与淋巴细胞比值 /
- T淋巴细胞亚群 /
- 相关性 /
- 预后
Abstract: Objective To investigate the correlation between the ratio of peripheral blood neutrophil to lymphocyte (NLR) level and T lymphocyte subsets in patients with multiple myeloma (MM) and its effect on prognosis. Methods Eighty patients with MM who were treated in Zhejiang Tongde Hospital from June 2016 to January 2018 were selected as the MM group; 60 healthy people who were examined in our hospital during the same period were selected as the healthy control group. The levels of NLR, peripheral blood T cell subsets and NK cells were compared between the two groups. Pearson method was used to analyse the correlation between NLR and T cell subsets levels in the MM group. In addition, the patients with MM were divided into the high NLR level group (NLR≥2.69; 38 cases) and low NLR level group (NLR < 2.69; 42 cases). The survival curves were drawn, and the survival rates were compared between the two groups. Results The levels of NLR and CD8⁺ in the MM group were significantly higher than those in the healthy control group [2.69±0.74 vs. 1.72±0.45, (44.34±5.04)% vs. (25.36±3.54)%, t=9.614, 26.133, all P < 0.05], the levels of CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in the MM group were obviously lower than those in the healthy control group (all P < 0.05), and no significant difference in the level of NK cells was found between the two groups (P>0.05). In the patients with MM, NLR negatively correlated with CD3⁺, CD4⁺, CD4⁺/CD8⁺ (r=-0.483, -0.481, -0.595, all P < 0.05) and positively correlated with CD8⁺ (r=0.318, P < 0.05). The two-year survival rate and the two-year progression-free survival rate of the high NLR group was obviously lower than those of the low NLR group (all P < 0.05). Conclusion The CD3⁺, CD4⁺ and CD4⁺/CD8⁺ levels in the patients with MM are obviously lower than those in healthy people, and the NLR and CD8⁺ levels in the patients with MM are obviously higher than those in healthy people. The level of NLR is closely related to the immune function of patients. High NLR levels and abnormal expression of peripheral T lymphocyte subsets suggest a poor prognosis in patients with MM.
- Multiple myeloma /
- Neutrophil to lymphocyte ratio /
- T lymphocyte subsets /
- Correlation /
- Prognosis

HTML全文

图 1 不同NLR水平MM患者生存曲线

下载: 全尺寸图片幻灯片

表 1 MM患者与健康对照组外周血T细胞亚群及NK细胞水平比较(x ±s)

组别	例数	CD3⁺(%)	CD4⁺(%)	CD8⁺(%)	CD4⁺/CD8⁺	NK细胞(%)
MM组	80	58.90±7.07	33.34±4.72	44.34±5.04	0.75±0.17	19.56±2.74
健康对照组	60	71.34±5.42	43.56±4.28	25.36±3.54	1.73±0.28	19.12±3.12
t值		-11.350	-13.177	26.133	-24.341	0.877
P值		< 0.001	< 0.001	< 0.001	< 0.001	0.382

下载: 导出CSV

参考文献(20)

[1]	张凯旋, 蒋端凤, 李晓聃, 等. 157例多发性骨髓瘤患者预后因素分析及分期评价[J]. 实用医学杂志, 2019, 35(14): 2238-2242. doi: 10.3969/j.issn.1006-5725.2019.14.010
[2]	姚卫芹, 朱明清, 颜灵芝, 等. 十色流式细胞术监测微小残留病对多发性骨髓瘤患者预后判断的意义[J]. 中华血液学杂志, 2019, 40(9): 720-721, 725.
[3]	马涛, 吴鹏强, 李晓明, 等. 双打击多发性骨髓瘤的临床特点及治疗反应分析[J]. 中国基层医药, 2020, 27(11): 1340-1344. doi: 10.3760/cma.j.issn.1008-6706.2020.11.014
[4]	陈海敏, 韦苇, 彭嵘, 等. R-ISS分期系统在初发412例多发性骨髓瘤中的临床应用[J]. 中国实验血液学杂志, 2019, 27(1): 110-104. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201901021.htm
[5]	蔡小平, 石岳坚, 郑翠苹, 等. 血清血小板因子4对采用沙利度胺联合VCD治疗的新发多发性骨髓瘤患者疗效的预测价值[J]. 中华全科医学, 2019, 17(12): 2035-2037, 2078. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201912016.htm
[6]	傅郁华, 胡晓霞, 陈莉, 等. RISS新分期系统对多发性骨髓瘤预后意义的评估分析[J]. 肿瘤, 2018, 38(4): 347-355. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL201804008.htm
[7]	刘红春, 黄国虹, 崔彦杰, 等. 中性粒细胞/淋巴细胞比值对多发性骨髓瘤患者的预后评估价值[J]. 国际检验医学杂志, 2020, 41(10): 1203-1205. doi: 10.3969/j.issn.1673-4130.2020.10.013
[8]	孙真真, 许德英, 王小利, 等. 外周血中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对初诊多发性骨髓瘤患者总生存情况的预测价值[J]. 中国慢性病预防与控制, 2020, 28(3): 213-217. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXB202003013.htm
[9]	谢世国. 外周血中性粒细胞与淋巴细胞比值对初治多发性骨髓瘤患者预后评估的价值[J]. 现代肿瘤医学, 2019, 27(11): 1988-1992. doi: 10.3969/j.issn.1672-4992.2019.11.033
[10]	赵泽昊, 孙海英. 初诊多发性骨髓瘤患者血液炎症指标与预后的相关性分析[J]. 现代肿瘤医学, 2019, 27(21): 3878-3881. doi: 10.3969/j.issn.1672-4992.2019.21.034
[11]	孙巨勇, 牟娜, 牟佳, 等. 中性白细胞/淋巴细胞比例和血小板/淋巴细胞比例变化在多发性骨髓瘤患者中的意义[J]. 中国实验血液学杂志, 2019, 27(4): 1185-1189. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201904036.htm
[12]	魏文波, 杜宇. 免疫细胞亚群与多发性骨髓瘤临床预后因子相关性研究[J]. 实用医院临床杂志, 2019, 16(2): 37-40. doi: 10.3969/j.issn.1672-6170.2019.02.012
[13]	蔡子仁, 王建, 周新明, 等. 开胸与胸腔镜手术影响肺癌患者术后调节T细胞功能和T淋巴细胞亚群的临床研究[J]. 河北医药, 2019, 41(19): 2944-2947. doi: 10.3969/j.issn.1002-7386.2019.19.016
[14]	黄国虹, 李智伟, 王昌敏. 不同免疫表型多发性骨髓瘤患者外周血淋巴细胞亚群分析[J]. 肿瘤研究与临床, 2018, 30(3): 176-179. doi: 10.3760/cma.j.issn.1006-9801.2018.03.008
[15]	宋斌, 万楚成, 张王刚, 等. 多发性骨髓瘤患者外周T淋巴细胞亚群和NK细胞比值与预后关系[J]. 标记免疫分析与临床, 2019, 26(1): 119-121. https://www.cnki.com.cn/Article/CJFDTOTAL-BJMY201901030.htm
[16]	孙延庆, 李青芬, 张启科, 等. 中性粒细胞/淋巴细胞比值在多发性骨髓瘤患者预后中的意义[J]. 中国实验血液学杂志, 2019, 27(2): 489-493. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY202101024.htm
[17]	崔壮壮, 张媛媛, 金北平, 等. 中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对初诊多发性骨髓瘤患者总生存和无进展生存的预测意义[J]. 解放军医学院学报, 2019, 40(2): 121-126. https://www.cnki.com.cn/Article/CJFDTOTAL-JYJX201902005.htm
[18]	丁婕, 顾炎, 赵四书, 等. 外周血T淋巴细胞亚群与初诊老年多发性骨髓瘤患者预后的相关性[J]. 中国实验血液学杂志, 2019, 27(6): 1876-1880. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201906031.htm
[19]	朱健伟, 孙超, 孙鸿丽, 等. 初诊外周血中性粒细胞与淋巴细胞比值对多发性骨髓瘤患者预后的影响[J]. 白血病·淋巴瘤, 2018, 27(5): 272-275. doi: 10.3760/cma.j.issn.1009-9921.2018.05.004
[20]	赵跃, 黄景昊, 孙甲甲, 等. 术前NLR、PLR、SⅡ与甲状腺乳头状癌临床病理特征的关系[J]. 中华全科医学, 2019, 17(5): 716-719, 737. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201905004.htm